AGP Executive Report
Last update: 11 hours agoCancer Research (Germany-linked): Akeso has enrolled its first patient in a global Phase III trial (COMPASSION-37) testing cadonilimab, a bispecific antibody, for advanced HER2-negative gastric cancer, comparing cadonilimab plus chemotherapy versus chemotherapy with or without nivolumab, with German investigator Markus Möhler among the leads. Diabetes Tech (Germany): FiberSense says it has completed the first automated sensor-fibre filling on a new line in Großostheim for its CE-marked 28-day optical CGM system, aiming to improve reproducibility as it prepares commercial launch. Mental Health (International comparison): A Statista Consumer Insights survey reports the highest self-reported mental health concerns in Australia (44%) and the US (41%), with Germany at 31% among adults aged 18–64. Healthcare Policy (Euthanasia debate): Pope Leo XIV renewed opposition to euthanasia and assisted dying during a Lourdes visit, criticizing “false compassion” and urging care for suffering patients. Home Health Manufacturing (Germany): IFA 2026 coverage highlights growing demand for space-saving at-home fitness devices, including KingSmith’s foldable treadmill and related products.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
